299 related articles for article (PubMed ID: 15219553)
1. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
Cooper DA; Lange JM
Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
[TBL] [Abstract][Full Text] [Related]
2. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
Matthews T; Salgo M; Greenberg M; Chung J; DeMasi R; Bolognesi D
Nat Rev Drug Discov; 2004 Mar; 3(3):215-25. PubMed ID: 15031735
[TBL] [Abstract][Full Text] [Related]
3. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
Fung HB; Guo Y
Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
[TBL] [Abstract][Full Text] [Related]
4. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
5. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
[TBL] [Abstract][Full Text] [Related]
6. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
[TBL] [Abstract][Full Text] [Related]
7. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
Jamjian MC; McNicholl IR
Am J Health Syst Pharm; 2004 Jun; 61(12):1242-7. PubMed ID: 15259753
[TBL] [Abstract][Full Text] [Related]
8. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.
Hardy H; Skolnik PR
Pharmacotherapy; 2004 Feb; 24(2):198-211. PubMed ID: 14998221
[TBL] [Abstract][Full Text] [Related]
9. Enfuvirtide.
Lalezari JP; Luber AD
Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
[TBL] [Abstract][Full Text] [Related]
10. Enfuvirtide: a review of its use in the management of HIV infection.
Oldfield V; Keating GM; Plosker G
Drugs; 2005; 65(8):1139-60. PubMed ID: 15907147
[TBL] [Abstract][Full Text] [Related]
11. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
Raffi F
Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550
[TBL] [Abstract][Full Text] [Related]
13. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
Lalezari JP; Bellos NC; Sathasivam K; Richmond GJ; Cohen CJ; Myers RA; Henry DH; Raskino C; Melby T; Murchison H; Zhang Y; Spence R; Greenberg ML; Demasi RA; Miralles GD;
J Infect Dis; 2005 Apr; 191(7):1155-63. PubMed ID: 15747252
[TBL] [Abstract][Full Text] [Related]
14. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
[TBL] [Abstract][Full Text] [Related]
15. Enfuvirtide (T-20): potentials and challenges.
Foy K; Juethner SN
J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017
[TBL] [Abstract][Full Text] [Related]
16. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
Pham PA
Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
[No Abstract] [Full Text] [Related]
17. Discontinuation of the clinical development of fusion inhibitor T-1249.
Martin-Carbonero L
AIDS Rev; 2004; 6(1):61. PubMed ID: 15168742
[No Abstract] [Full Text] [Related]
18. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
Wheeler DA; Lalezari JP; Kilby JM; Wheat J; Delehanty J; DeMasi R; Patel I; Salgo M
J Clin Virol; 2004 Jun; 30(2):183-90. PubMed ID: 15125875
[TBL] [Abstract][Full Text] [Related]
19. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
20. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Pan C; Cai L; Lu H; Qi Z; Jiang S
J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
